A low-fluence 1064-nm Q-switched neodymium-doped yttrium aluminium garnet laser for the treatment of café-au-lait macules - 17/08/15
Abstract |
Background |
Café-au-lait macules (CALMs) are a common pigmentary disorder. Although a variety of laser modalities have been used to treat CALMs, their efficacies vary and dyspigmentation may develop.
Objective |
We evaluated the clinical efficacy and safety of a low-fluence 1064-nm Q-switched neodymium-doped yttrium aluminium garnet (Nd:YAG) laser for the treatment of CALMs.
Methods |
In a preliminary investigation, 6 patients underwent a split-lesion comparative study with 532- and 1064-nm Q-switched Nd:YAG laser treatment. In total, 32 patients with 39 CALMs were enrolled in a subsequent prospective trial to evaluate the treatment with a low-fluence 1064-nm Q-switched Nd:YAG laser.
Results |
In the preliminary study, the 1064-nm treatment group had a more favorable response and a shorter recovery time. In a subsequent prospective trial of a 1064-nm laser, 74.4% of the lesions showed a clinical response with clearance of ≥50.0%. The treatment regimen was well tolerated; 15.4% of patients experienced adverse events.
Limitations |
The study participants were followed for 6 months, and there were no relevant treatment controls in the prospective trial group.
Conclusion |
Low-fluence 1064-nm Q-switched Nd:YAG laser therapy afforded good clinical improvement for treating CALMs.
Le texte complet de cet article est disponible en PDF.Key words : 1064-nm Q-switched Nd:YAG laser, café-au-lait macules, laser therapy
Plan
| Supported by a grant (HN10C0013) of the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (awarded to Y. L., Y.J. S. and M. I.). |
|
| Conflicts of interest: None declared. |
Vol 73 - N° 3
P. 477-483 - septembre 2015 Retour au numéro
Article précédent
- Squaric acid sensitization is not required for response in the treatment of alopecia areata
- Priyanka Vedak, Daniela Kroshinsky
- Low-dose methotrexate-induced skin toxicity: Keratinocyte dystrophy as a histologic marker
- Julie Delyon, Nicolas Ortonne, Emmanuel Benayoun, Julien Moroch, Pierre Wolkenstein, Emilie Sbidian, Olivier Chosidow
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?